Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 1097-1100

  Balakrishnan, Kumudha ^a   Aggarwal, Sumesh ^a   Wierda, William ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOGOSSYPOLONE; APOPTOSIS INDUCING FACTOR; BH3 PROTEIN; GOSSYPOL; MESSENGER RNA; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER INHIBITION; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; GENE SILENCING; HYPOKALEMIA; KNOCKOUT MOUSE; LETTER; LEUKEMIA CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; GOSSYPOL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE;

EID: 84876227417     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.718344     Document Type: Letter

References (22)

1. Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807-3817.
2. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379-3389.
3. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89: 630-643.
4. Pepper C, Thomas A, Hoy T, Cotter F, Bentley P. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107: 611-615.
5. O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick S C, Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:7697-7702.
6. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996;381:335-341.
7. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46:4259-4264.
8. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006;13:1419-1421.
9. Becattini B, Kitada S, Leone M, et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 2004; 11: 389-395.
10. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112:1971-1980.
11. Zhan Y, Jia G, Wu D, Xu Y, Xu L. Design and synthesisofagossypol derivative with improved antitumor activities. Arch Pharm (Weinheim) 2009;342:223-229.
12. Mohammad RM YD, Chen B, Aboukameel A, Chen J, Nikolovska-Coleska Z, Al-Katib A and Wang S. ApoG2, a potent, non-toxic small-molecule inhibitor of Bcl-2 family: a preclinical trial in lymphoma. Proc Am Assoc Cancer Res 2006; 47: Abstract 1335.
13. Arnold AA, Aboukameel A, Chen J, et al. Preclinical studies of apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol Cancer 2008; 7: 20.
14. Sun Y, Wu J, Aboukameel A, et al. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ter 2008;7:1418-1426.
15. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
16. Degenhardt K, Sundararajan R, Lindsten T, Tompson C, White E. Bax and Bak independently promote cytochrome C release from mitochondria. J Biol Chem 2002;277:14127-14134.
17. Choi S, Singh SV. Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res 2005;65:2035-2043.
18. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009;113:149-153.
19. Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 2008;283:9580-9586.
20. Lee EF, Czabotar PE, van Delft MF, et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 2008;180:341-355.
21. Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010;6:595-601.
22. Doi K, Li R, Sung SS, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012;287:10224-10235.